GPP
LXRX icon

Great Point Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Great Point Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,000
Closed -$50.4K – 35
2024
Q2 		$50.4K Buy
+30,000
New +$53.8K 0.01% 33

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Great Point Partners's LXRX Position: Q3 2024 in Review

Great Point Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2024, closing a stake of 30,000 shares — an estimated $50.4K sold.

Great Point Partners first reported a position in LXRX in Q2 2024 and held it in 1 quarter. The position peaked at $50.4K in Q2 2024. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2024.

  • Great Point Partners reported no remaining Lexicon Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Great Point Partners sold 30,000 Lexicon Pharmaceuticals shares in Q3 2024, an estimated $50.4K.
  • Great Point Partners first reported a position in Lexicon Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Great Point Partners's Lexicon Pharmaceuticals position peaked at $50.4K in Q2 2024.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2024.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.